We are studying whether volrustomig is safe and effective for adults with advanced head and neck cancer who have recently completed chemoradiotherapy without surgery. This trial compares the treatment to observation to see which approach may help patients more.
We are evaluating a new medication for adolescents with moderate to severe plaque psoriasis to see if it helps improve their skin condition compared to a placebo. The study also looks at safety and how patients feel about their treatment.
We are studying the safety and effects of radiprodil on seizures and behavior in patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II. This research may help improve treatment options for these conditions.
We are studying the safety and effectiveness of pembrolizumab alone or with new investigational treatments for people with melanoma. This research aims to find better options for managing this type of skin cancer.
We are testing a new oral medication for adults with major depressive disorder to see if it helps improve their symptoms compared to a placebo. The study will measure changes in mood and daily functioning over six weeks.
We are investigating how serotonin receptors relate to impulsivity in adults with Tourette's syndrome. This study may help us understand brain activity and behavior during treatment.
We are studying a new treatment combining MK-2870 with Enfortumab Vedotin and Pembrolizumab for patients with advanced bladder cancer. The goal is to assess safety and how well it works compared to existing options.
We are testing a new combination of medications for patients with high-risk chronic lymphocytic leukemia who haven't been treated before. The study aims to see if this new treatment can help keep the disease from progressing better than standard options.
We are researching how well finerenone and semaglutide can lower albuminuria in patients with chronic kidney disease. The goal is to find the most effective treatment for each individual and explore remote monitoring options.
We are studying whether the combination of baxdrostat and dapagliflozin is more effective than dapagliflozin alone for adults with chronic kidney disease and high blood pressure. The trial will assess its impact on kidney health and heart-related risks.
We are studying a new treatment for children and young adults with advanced cancers that have specific genetic changes. The trial aims to evaluate how well it works and its safety.
We are studying whether fasudil can help prevent memory loss in people with early Alzheimer's disease. The trial will also assess its safety and effects on brain health.
We are studying a new therapy to see if it can improve motor symptoms in adults with moderate Parkinson's Disease. The trial also looks at safety and overall quality of life for participants.
We are studying whether propranolol can help reduce anxiety in patients undergoing surgery for pancreatic cancer and if it affects tumor-related changes. This trial will compare the effects of propranolol to a placebo in a small group of participants.
We are studying the best treatment options for lung disease caused by Mycobacterium abscessus. Our goal is to see how well these treatments clear the infection and how well patients tolerate them.
We are testing a new drug called Bleximenib for people with acute leukemia to find the best dose and check its safety. We also want to see if it helps improve treatment outcomes.
We are testing a new drug, bleximenib, combined with current therapies for patients with acute myeloid leukemia who have certain genetic changes. The goal is to find the best dose and ensure it is safe for use.
We are studying whether adding ketamine to venlafaxine helps hospitalized patients with severe depression feel better faster than a placebo. We’re also looking at its effects on hospital stay and side effects.
We are studying whether a single daily dose of immunosuppressive medication is as effective as a twice-daily dose for liver transplant recipients. This trial also compares two different formulations of tacrolimus to see which works better.
We are investigating whether a six-week intensified medication plan helps individuals with schizophrenia who didn't respond to their first treatment. The study looks at changes in symptoms, functioning, and overall well-being compared to standard care.